Skip to main
  1. Stocks
  2. Prelude Therapeutics
  3. Forecast
PRLD

Prelude Therapeutics (PRLD) Stock Forecast & Price Target

Prelude Therapeutics (PRLD) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Prelude Therapeutics is supported by a pipeline focused on high-unmet-need oncology targets, including selective KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors, and next-generation degrader antibody conjugates with transformative potential. Its 3Q26 net loss of $0.12 per share was in line with expectations, with R&D of about $14.8M, SG&A of $5.1M, and cash, cash equivalents, and marketable securities of roughly $142.7M. That balance sheet should fund operations into 2Q28, while upcoming catalysts in ASH 2026, SABCS 2026, 1H27, and 2H27 provide multiple opportunities to validate the platform and expand partnering value.

Bears say

Prelude Therapeutics is a high-risk, pre-commercial oncology name whose valuation depends heavily on clinical execution rather than current earnings power. Its focus on selective KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors, and degrader antibody conjugates offers scientific upside, but the company remains exposed to the binary risk that these programs fail to deliver transformative data or regulatory momentum. With no mention of profitability or recurring revenue support, the stock’s fundamentals appear fragile and highly dependent on pipeline progress in a competitive precision oncology market.

Prelude Therapeutics (PRLD) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prelude Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Prelude Therapeutics (PRLD) Analyst Forecast & Price Prediction

Get the latest Prelude Therapeutics (PRLD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Prelude Therapeutics (PRLD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prelude Therapeutics (PRLD) Forecast

Analysts have given Prelude Therapeutics (PRLD) a Buy based on their latest research and market trends.

According to 4 analysts, Prelude Therapeutics (PRLD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prelude Therapeutics (PRLD)


Prelude Therapeutics (PRLD) Analyst Forecast & Price Prediction

Get the latest Prelude Therapeutics (PRLD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Prelude Therapeutics (PRLD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRLD stock data and trends